CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 400 enrolled
Drug / intervention
pegylated interferon alpha and ribavirindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00687999
NCT00687999N/ACompleted
CompareCT.gov

Non-insulin-dependent Diabetes Mellitus and Insulin Resistance in Chronic Hepatitis C Patients Treated With Combination Therapy With Pegylated Interferon and Ribavirin in Taiwan

Kaohsiung Medical University Chung-Ho Memorial Hospital·interventional·Posted Jun 2, 2008·Updated Aug 6, 2009

In Brief

A clinical study evaluating pegylated interferon alpha and ribavirin for Chronic Hepatitis C and Insulin Resistance. Completed, enrolled 400 participants across 1 site.

Detailed Summary

The influence of insulin sensitivity and glucose tolerance on the effects of antiviral therapy for HCV remains unclear. The aim of the present study was (1) To elucidate the clinical and virological factors associated with sustained viral response in patients with combination therapy with PEG-IFN and ribavirin. (2) To clarify the influence of diabetes mellitus (DM), impaired glucose tolerance test (IGT) and insulin resistance (IR) on the HCV response to combination therapy with PEG-IFN and ribavirin. (3) To test the influence of combination therapy on HOMA IR

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Hepatitis C, Insulin Resistance
CountriesTaiwan
CollaboratorsNational Science and Technology Council, Taiwan

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2008
Enrollment StartDec 1, 2005
Primary CompletionJun 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.1 years ago

Interventions

pegylated interferon alpha and ribavirindrug

standard pegylated interferon alpha and ribavirin